DIGITAL NEWSROOM

Featured post

January 19, 2022

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test

Read more »

Featured post

January 09, 2022

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Read more »

Featured post

January 09, 2022

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences and OncXerna Announce Licensing Agreement

Read more »

January 19, 2022

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients
January 09, 2022

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results
January 09, 2022

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
January 09, 2022

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients
December 09, 2021

Exact Sciences Commits $500,000 to Urban League Black Business Hub
December 08, 2021

New Data Presented at SABCS^® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making
December 01, 2021

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test
November 23, 2021

New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
November 18, 2021

Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection
October 26, 2021

New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening
September 14, 2021

Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients
September 02, 2021

Exact Sciences to Present New Oncotype DX Genomic Prostate Score^® Test Data and Exhibit its Full Urology Portfolio at the 2021 Virtual AUA Annual Meeting

Choose your country or region:

DIGITAL NEWSROOM

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Exact Sciences Commits $500,000 to Urban League Black Business Hub

New Data Presented at SABCS^® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test

New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients

Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection

New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening

Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

Exact Sciences to Present New Oncotype DX Genomic Prostate Score^® Test Data and Exhibit its Full Urology Portfolio at the 2021 Virtual AUA Annual Meeting

Multimedia

Quick Links

Choose your country or region:

DIGITAL NEWSROOM

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Exact Sciences Commits $500,000 to Urban League Black Business Hub

New Data Presented at SABCS® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test

New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients

Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection

New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening

Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

Exact Sciences to Present New Oncotype DX Genomic Prostate Score® Test Data and Exhibit its Full Urology Portfolio at the 2021 Virtual AUA Annual Meeting

Multimedia

Quick Links

Follow us on

New Data Presented at SABCS^® 2021 Strengthen Value of Oncotype DX Breast Recurrence Score^® Test to Inform Clinical Decision-making

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX^® Test

Exact Sciences to Present New Oncotype DX Genomic Prostate Score^® Test Data and Exhibit its Full Urology Portfolio at the 2021 Virtual AUA Annual Meeting